{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:34:24Z","timestamp":1767850464806,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00404-015-3987-4","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T06:34:53Z","timestamp":1450679693000},"page":"1101-1106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome"],"prefix":"10.1007","volume":"293","author":[{"given":"Nur","family":"\u015eahin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesin","family":"Apayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emrah","family":"T\u00f6z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oya Nermin","family":"Sivrikoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mine","family":"Gen\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcl\u00fczar Arzu","family":"Turan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Eskicio\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"issue":"12","key":"3987_CR1","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/humrep\/dei253","volume":"20","author":"R Klemetti","year":"2005","unstructured":"Klemetti R, Sevon T, Gissler M, Hemminki M (2005) Complications of IVF and ovulation induction. Hum Reprod 20(12):3293\u20133300","journal-title":"Hum Reprod"},{"issue":"10","key":"3987_CR2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/humrep\/12.10.2167","volume":"12","author":"JA Stewart","year":"1997","unstructured":"Stewart JA, Hamilton PJ, Murdoch AP (1997) Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 12(10):2167\u20132173","journal-title":"Hum Reprod"},{"key":"3987_CR3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(94)93001-5","volume":"344","author":"N McClure","year":"1994","unstructured":"McClure N, Healy DL, Rogers PA et al (1994) Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344:235\u2013236","journal-title":"Lancet"},{"key":"3987_CR4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/humrep\/der349","volume":"27","author":"D Pietrowski","year":"2012","unstructured":"Pietrowski D, Szabo L, Sator M et al (2012) Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. Hum Reprod 27:196\u2013199","journal-title":"Hum Reprod"},{"key":"3987_CR5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","volume":"17","author":"C Carizza","year":"2008","unstructured":"Carizza C, Abdelmassih V, Abdelmassih S et al (2008) Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 17:751\u2013755","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"3987_CR6","first-page":"221","volume":"6","author":"X Liu","year":"2013","unstructured":"Liu X, Chen HH, Zhang LW (2013) Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy. Int J Ophthalmol 6(2):221\u2013227","journal-title":"Int J Ophthalmol"},{"issue":"17","key":"3987_CR7","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1073\/pnas.0308342101","volume":"101","author":"H Liu","year":"2004","unstructured":"Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY (2004) Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 101(17):6605\u20136610","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"3987_CR8","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2174\/092986607781483705","volume":"14","author":"S Yamagishi","year":"2007","unstructured":"Yamagishi S, Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, Okuda S (2007) Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 14(8):832\u2013835","journal-title":"Protein Pept Lett"},{"issue":"3","key":"3987_CR9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.mvr.2006.03.001","volume":"71","author":"S Yamagishi","year":"2006","unstructured":"Yamagishi S, Matsui T, Nakamura K, Yoshida T, Shimizu K, Takegami Y, Shimizu T, Inoue H, Imaizumi T (2006) Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res 71(3):222\u2013226","journal-title":"Microvasc Res"},{"key":"3987_CR10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3109\/00016341003592537","volume":"89","author":"A Saylan","year":"2010","unstructured":"Saylan A, Arioz DT, Koken T et al (2010) Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 89:692\u2013699","journal-title":"Acta Obstet Gynecol Scand"},{"key":"3987_CR11","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1097\/00029330-200812010-00014","volume":"121","author":"XM Tong","year":"2008","unstructured":"Tong XM, Zhang SY, Song T et al (2008) Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Chin Med J (Engl) 121:2434\u20132439","journal-title":"Chin Med J (Engl)"},{"key":"3987_CR12","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","volume":"147","author":"R Gomez","year":"2006","unstructured":"Gomez R, Gonzalez-Izquierdo M, Zimmermann RC et al (2006) Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability with-out altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147:5400\u20135411","journal-title":"Endocrinology"},{"key":"3987_CR13","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.2007-0409","volume":"92","author":"C Alvarez","year":"2007","unstructured":"Alvarez C, Marti-Bonmati L, Novella-Maestre E et al (2007) Dopamine agonist capergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931\u20132937","journal-title":"J Clin Endocrinol Metab"},{"key":"3987_CR14","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.fertnstert.2007.09.028","volume":"90","author":"R Quintana","year":"2008","unstructured":"Quintana R, Kopcow L, Marconi G et al (2008) Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil Steril 90:1511\u20131516","journal-title":"Fertil Steril"},{"key":"3987_CR15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1196\/annals.1386.022","volume":"1089","author":"T Hong","year":"2006","unstructured":"Hong T, Cheng S (2006) Aromatase inhibitors: structural features and biochemical characterization. Ann N Y Acad Sci 1089:237\u2013251","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"3987_CR16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1472-6483(10)60040-5","volume":"19","author":"A Delvigne","year":"2009","unstructured":"Delvigne A (2009) Symposium: update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online 19(1):8\u201313 (review)","journal-title":"Reprod Biomed Online"},{"key":"3987_CR17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1196\/annals.1386.022","volume":"1089","author":"Y Hong","year":"2006","unstructured":"Hong Y, Chen S (2006) Aromatase inhibitors: structural features and biochemical characterization. Ann N Y Acad Sci 1089:237\u2013251 (review)","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"3987_CR18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/19396368.2014.957879","volume":"60","author":"Qiaohua He","year":"2014","unstructured":"He Qiaohua, Liang Linlin, Zhang Cuilian, Li Hangsheng, Zhaojia Ge Lu, Wang Shihong Cui (2014) Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med 60(6):355\u2013360","journal-title":"Syst Biol Reprod Med"},{"issue":"6","key":"3987_CR19","first-page":"869","volume":"45","author":"YQ Wang","year":"2013","unstructured":"Wang YQ, Yang J, Xu WM, Xie QZ, Yan WJ, Yin TL, Cheng D, Xiao ZN, Li J (2013) Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome. Beijing Da Xue Xue Bao 45(6):869\u2013872","journal-title":"Beijing Da Xue Xue Bao"},{"issue":"2","key":"3987_CR20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/0974-1208.86080","volume":"4","author":"P Kumar","year":"2011","unstructured":"Kumar P, Sait SF, Sharma A, Kumar M (2011) Ovarian hyperstimulation syndrome. J Hum Reprod Sci 4(2):70\u201375","journal-title":"J Hum Reprod Sci"},{"issue":"4","key":"3987_CR21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/humupd\/dmn008","volume":"14","author":"SR Soares","year":"2008","unstructured":"Soares SR, G\u00f3mez R, Sim\u00f3n C, Garc\u00eda-Velasco JA, Pellicer A (2008) Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 14(4):321\u2013333","journal-title":"Hum Reprod Update."},{"issue":"6","key":"3987_CR22","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/humrep\/det027","volume":"28","author":"D Chuderland","year":"2013","unstructured":"Chuderland D, Hasky N, Ben-Ami I, Kaplan-Kraicer R, Grossman H, Shalgi R (2013) A physiological approach for treating endometriosis by recombinant pigment epithelium-derived factor (PEDF). Hum Reprod 28(6):1626\u20131634","journal-title":"Hum Reprod"},{"key":"3987_CR23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1472-6483(10)60044-2","volume":"19","author":"CE Busso","year":"2009","unstructured":"Busso CE, Garcia-Velasco J, Gomez R et al (2009) Symposium: update on prediction and management of OHSS. Prevention of OHSS\u2013dopamine agonists. Reprod Biomed Online 19:43\u201351","journal-title":"Reprod Biomed Online"},{"issue":"1\u20132","key":"3987_CR24","first-page":"48","volume":"60","author":"H Amir","year":"2015","unstructured":"Amir H, Yaniv D, Hasson J, Amit A, Gordon D, Azem F (2015) Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. J Reprod Med 60(1\u20132):48\u201354","journal-title":"J Reprod Med"},{"key":"3987_CR25","first-page":"1","volume":"5","author":"M Kasum","year":"2014","unstructured":"Kasum M, Vr\u010di\u0107 H, Stani\u0107 P, Je\u017eek D, Ore\u0161kovi\u0107 S, Beketi\u0107-Ore\u0161kovi\u0107 L, Pekez M (2014) Dopamine agonists in prevention of ovarian hyperstimulation syndrome. Gynecol Endocrinol 5:1\u20135","journal-title":"Gynecol Endocrinol"},{"issue":"9","key":"3987_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1477-7827-9-85","volume":"21","author":"EG Papanikolaou","year":"2011","unstructured":"Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H, Tarlatzis B (2011) Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol 21(9):85","journal-title":"Reprod Biol Endocrinol"},{"key":"3987_CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.fertnstert.2008.04.042","volume":"92","author":"JA Garcia-Velasco","year":"2009","unstructured":"Garcia-Velasco JA, Quea G, Piro M et al (2009) Letrozle administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril 92:222\u2013225","journal-title":"Fertil Steril"},{"issue":"1","key":"3987_CR28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejogrb.2010.09.003","volume":"154","author":"ST Ceyhan","year":"2011","unstructured":"Ceyhan ST, Onguru O, Fidan U, Ide T, Yaman H, Kilic S, Baser I (2011) Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model. Eur J Obstet Gynecol Reprod Biol 154(1):100\u2013104","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"3987_CR29","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.fertnstert.2014.07.1240","volume":"102","author":"H Ferrero","year":"2014","unstructured":"Ferrero H, Garc\u00eda-Pascual CM, Morales C, Sim\u00f3n C, Gayt\u00e1n F, Pellicer A, G\u00f3mez R (2014) Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. Fertil Steril 102(5):1468\u20131476","journal-title":"Fertil Steril"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-015-3987-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-015-3987-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-015-3987-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T15:48:59Z","timestamp":1567439339000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-015-3987-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3987"],"URL":"https:\/\/doi.org\/10.1007\/s00404-015-3987-4","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,21]]}}}